182 related articles for article (PubMed ID: 38251523)
1. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.
Bolhuis TE; Marsman DE; den Broeder AA; den Broeder N; van der Maas A
Lancet Rheumatol; 2023 Apr; 5(4):e208-e214. PubMed ID: 38251523
[TBL] [Abstract][Full Text] [Related]
2. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
Saraux A; Le Henaff C; Dernis E; Carvajal-Alegria G; Tison A; Quere B; Petit H; Felten R; Jousse-Joulin S; Guellec D; Marhadour T; Kervarrec P; Cornec D; Querellou S; Nowak E; Souki A; Devauchelle-Pensec V
Lancet Rheumatol; 2023 Dec; 5(12):e728-e735. PubMed ID: 38251563
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
4. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
Bonelli M; Radner H; Kerschbaumer A; Mrak D; Durechova M; Stieger J; Husic R; Mandl P; Smolen JS; Dejaco C; Aletaha D
Ann Rheum Dis; 2022 Jun; 81(6):838-844. PubMed ID: 35210264
[TBL] [Abstract][Full Text] [Related]
6. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
Salvarani C; Macchioni P; Manzini C; Paolazzi G; Trotta A; Manganelli P; Cimmino M; Gerli R; Catanoso MG; Boiardi L; Cantini F; Klersy C; Hunder GG
Ann Intern Med; 2007 May; 146(9):631-9. PubMed ID: 17470831
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
[TBL] [Abstract][Full Text] [Related]
8. Concordance and agreement between different activity scores in polymyalgia rheumatica.
D'Agostino J; Souki A; Lohse A; Carvajal Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel B; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A; Devauchelle-Pensec V
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38490696
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N; Schmidt WA; Bergner R; Rech J; Unger L; Tony HP; Finzel S; Andreica I; Kofler DM; Weiner SM; Lamprecht P; Schulze-Koops H; App C; Pournara E; Mendelson MH; Sieder C; Maricos M; Thiel J
Lancet Rheumatol; 2023 Jun; 5(6):e341-e350. PubMed ID: 38251601
[TBL] [Abstract][Full Text] [Related]
10. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
11. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
12. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.
Christ L; Seitz L; Scholz G; Sarbu AC; Amsler J; Bütikofer L; Tappeiner C; Kollert F; Reichenbach S; Villiger PM
Lancet Rheumatol; 2021 Sep; 3(9):e619-e626. PubMed ID: 38287611
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
Front Immunol; 2019; 10():1981. PubMed ID: 31507597
[TBL] [Abstract][Full Text] [Related]
15. [
Allard B; Devauchelle-Pensec V; Saraux A; Nowak E; Tison A; Boukhlal S; Guellec D; Jousse-Joulin S; Cornec D; Marhadour T; Le Pennec R; Salaün PY; Querellou S
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1297-1309. PubMed ID: 38095675
[TBL] [Abstract][Full Text] [Related]
16. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
17. Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?
Marsman DE; den Broeder N; Boers N; van den Hoogen FHJ; den Broeder AA; van der Maas A
Clin Exp Rheumatol; 2021; 39(1):32-37. PubMed ID: 32242804
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC
Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera RF; Unizony S; Warrington KJ; Sloane J; Giannelou A; Nivens MC; Akinlade B; Wong W; Bhore R; Lin Y; Buttgereit F; Devauchelle-Pensec V; Rubbert-Roth A; Yancopoulos GD; Marrache F; Patel N; Dasgupta B;
N Engl J Med; 2023 Oct; 389(14):1263-1272. PubMed ID: 37792612
[TBL] [Abstract][Full Text] [Related]
20. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
